{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:29:39Z","timestamp":1790357379411,"version":"4.1.0"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,14]]},"DOI":"10.1093\/ehjcvp\/pvae035","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T01:22:06Z","timestamp":1715908926000},"page":"371-373","source":"Crossref","is-referenced-by-count":6,"title":["After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-7758","authenticated-orcid":false,"given":"Juan","family":"Tamargo","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense , Plaza de Ram\u00f3n y Cajal s\/n, 28040 Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"2024081413471600000_bib1","doi-asserted-by":"crossref","first-page":"P2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"GBD 2021 Causes of Death Collaborators","year":"2024","journal-title":"Lancet"},{"key":"2024081413471600000_bib2","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2024081413471600000_bib3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1139\/cjpp-2022-0010","article-title":"Aprocitentan and the endothelin system in resistant hypertension","volume":"100","author":"Clozel","year":"2022","journal-title":"Can J Physiol Pharmacol"},{"key":"2024081413471600000_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11906-023-01259-z","article-title":"Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension","volume":"25","author":"Heidari Nejad","year":"2023","journal-title":"Curr Hypertens Rep"},{"key":"2024081413471600000_bib5","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","article-title":"Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension","volume":"75","author":"Verweij","year":"2020","journal-title":"Hypertension"},{"key":"2024081413471600000_bib6","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae035\/58710340\/pvae035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/5\/371\/58818475\/pvae035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/5\/371\/58818475\/pvae035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T13:48:18Z","timestamp":1723643298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/5\/371\/7675498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":6,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,16]]},"published-print":{"date-parts":[[2024,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae035","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,5,16]]}}}